Quiver Bioscience Inc.

Quiver Bioscience Inc., a for-profit biopharmaceutical research company based in Cambridge, Massachusetts, receives federal research funding exclusively as a prime recipient of National Institutes of Health (NIH) grants focused on neurological drug discovery and antisense oligonucleotide (ASO) therapeutics development. The company does not hold federal contracts and operates entirely within the federal grant ecosystem, competing in open solicitations from NIH institutes.

Quiver's federal footprint centers on three NIH customer institutes within the Department of Health and Human Services. The National Institute of Neurological Disorders and Stroke (NINDS) funds four awards totaling approximately $22.4 million, while the National Institute of Mental Health (NIMH) funds three awards, and the National Cancer Institute (NCI) funds one award. The company's recent awards include a $1.99 million Cooperative Agreement from NINDS (awarded April 24, 2026, completion March 31, 2028) to develop Nav1.7-targeting antisense oligonucleotides for chronic pain treatment using machine learning and all-optical electrophysiology screening in patient-derived induced pluripotent stem cells; a direct-to-Phase-II grant from NINDS (awarded May 20, 2025, completion April 30, 2028) for the SAFE-OPTION platform to predict ASO neurotoxicity in the central nervous system; a Phase II grant from NIMH (awarded September 19, 2023, completion August 31, 2025) for the BRITE-EYE discovery engine combining CRISPR screening, all-optical physiology, and machine learning to identify CNS therapeutic targets; and a Phase IIB grant from NINDS (awarded September 15, 2022, completion August 31, 2025) for development and commercialization of the Swarm 2.0 ultra-high-throughput optical plate reader for neurological drug screening.

Activity is sparse and episodic — one award annually across 2020, 2022, 2023, 2025, and 2026, with combined dollars obligated at $34.3 million across eight total awards. Two awards reach ultimate completion within the next twenty-four months (BRITE-EYE and the Swarm 2.0 platform work), creating recompete opportunity. Quiver's grant work is strictly as a prime recipient with no documented subcontracting role; the company's competitive posture centers on NIH peer-reviewed discovery funding for proprietary all-optical electrophysiology platforms, machine-learning-driven ASO design, and human neuronal functional assay development supporting preclinical CNS therapeutics pipelines.